UNICYCIVE THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $2.46 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-12
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $180.00K.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $2.29M, a 188.87% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$1.81M, a 286.82% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $775.00K.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$2.50M, a 417.09% decline from fiscal 2024.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $790.00K, a 38.09% decline from fiscal 2023.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $1.28M, a 0.71% increase from fiscal 2022.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $1.27M, a 2.10% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $180.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.46M 10-Q · filed 2026-08-12 | $651.00K derived: sum of 3 quarters · filed 2026-08-12 | $1.43M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.29M 10-Q · filed 2026-05-12 | $471.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.25M derived: sum of 3 quarters · filed 2026-05-12 | -$1.01M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$1.04M derived: sum of 2 quarters · filed 2026-03-30 | -$3.30M derived: sum of 3 quarters · filed 2026-08-12 | -$2.50M 10-K · filed 2026-03-30 |
| 2025-09-30 | $775.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.48M derived: sum of 2 quarters · filed 2026-08-12 | -$691.00K 10-Q · filed 2025-11-12 | $280.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$2.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$1.47M 10-Q · filed 2026-08-12 | -$495.00K derived: sum of 3 quarters · filed 2026-08-12 | -$1.13M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $791.00K 10-Q · filed 2026-05-12 | $1.76M derived: sum of 2 quarters · filed 2026-05-12 | $1.13M derived: sum of 3 quarters · filed 2026-05-12 | $759.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $971.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $340.00K derived: sum of 2 quarters · filed 2026-03-30 | -$32.00K derived: sum of 3 quarters · filed 2026-03-30 | $790.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | -$631.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.00M derived: sum of 2 quarters · filed 2025-11-12 | -$181.00K 10-Q · filed 2025-11-12 | $246.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$372.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $450.00K 10-Q · filed 2025-08-14 | $877.00K derived: sum of 3 quarters · filed 2025-08-14 | $2.36M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $822.00K 10-Q · filed 2025-05-14 | $1.25M derived: sum of 2 quarters · filed 2025-05-14 | $2.73M derived: sum of 3 quarters · filed 2025-05-14 | $2.29M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $427.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.91M derived: sum of 2 quarters · filed 2025-03-31 | $1.47M derived: sum of 3 quarters · filed 2025-03-31 | $1.28M 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.04M derived: sum of 2 quarters · filed 2024-11-13 | $849.00K 10-Q · filed 2024-11-13 | $208.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$442.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$635.00K 10-Q · filed 2024-08-14 | -$1.28M derived: sum of 3 quarters · filed 2024-08-14 | $678.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$193.00K 10-Q · filed 2024-05-13 | -$834.00K derived: sum of 2 quarters · filed 2024-05-13 | $1.12M derived: sum of 3 quarters · filed 2024-05-13 | $1.05M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$641.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.31M derived: sum of 2 quarters · filed 2024-03-28 | $1.24M derived: sum of 3 quarters · filed 2024-03-28 | $1.27M 10-K · filed 2024-03-28 |
| 2022-09-30 | $1.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.88M derived: sum of 2 quarters · filed 2023-11-14 | $1.91M 10-Q · filed 2023-11-14 | $2.69M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$70.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$46.00K 10-Q · filed 2023-08-14 | $732.00K derived: sum of 3 quarters · filed 2023-08-14 | $1.18M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $24.00K 10-Q · filed 2023-05-16 | $802.00K derived: sum of 2 quarters · filed 2023-05-16 | $1.25M derived: sum of 3 quarters · filed 2023-05-16 | $1.35M derived: sum of 4 quarters · filed 2023-05-16 |
| 2021-12-31 | $778.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $1.22M derived: sum of 2 quarters · filed 2023-03-31 | $1.32M derived: sum of 3 quarters · filed 2023-03-31 | $1.24M 10-K · filed 2023-03-31 |
| 2021-09-30 | $443.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $546.00K derived: sum of 2 quarters · filed 2022-11-14 | $463.00K 10-Q · filed 2022-11-14 | $483.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $103.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $20.00K 10-Q · filed 2022-08-15 | $40.00K derived: sum of 3 quarters · filed 2022-08-15 | -$160.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$83.00K 10-Q · filed 2022-05-12 | -$63.00K derived: sum of 2 quarters · filed 2022-05-12 | -$263.00K derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$180.00K derived: sum of 2 quarters · filed 2022-03-31 | -$68.00K 10-K · filed 2022-03-31 | |
| 2020-09-30 | -$200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$88.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $112.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |